Skip to main content

Hematological Disorders Diagnostic and Therapeutic Market is Expecting Worldwide Growth by 2021 – Persistence Market Research Study

Press Release   •   Feb 03, 2017 01:35 EST

In terms of geography, North America dominates the global hematological disorders diagnostic and therapeutic market. This is due to increased awareness about blood diseases and technological advancement in diagnostic procedures in the region. The U.S. represents the largest market for hematological disorders diagnostic and therapeutic in North America, followed by Canada. In Europe, Germany, France, the U.K., Italy and Spain account for a major share of the hematological disorders diagnostic and therapeutic market. This market in Asia is expected to expand at a significant rate over the next five years. This is due to various companies setting up manufacturing facilities in the region. Moreover, increasing awareness about blood disorders and rise in geriatric population are also driving the growth of the market in the region. India, China and Japan are expected to be the fastest growing hematological disorders diagnostic and therapeutic markets in Asia.

A sample of this report is available upon request @ http://www.persistencemarketresearch.com/samples/4096

In recent times, increased demand of diagnostic and therapeutic products for the management of blood diseases is key driver of the global hematological disorders diagnostic and therapeutic market. Increased investments in R&D in the pharmaceutical sector, lack of curative drugs for blood diseases, and the introduction of innovative drugs have also fueled the growth of this market. The ongoing development of drugs with properties, such as improved safety and high patient compliance, are also supporting the growth of the global hematological disorders diagnostic and therapeutic market. Therapies such as biological therapy, physiotherapy, chemotherapy, and radiation therapy have immense potential to spur the growth of this market.

However, stringent regulations by various governments hamper the growth of global hematological diagnostic and therapeutic market. Moreover, the patent expiries of some blockbuster drugs (drugs that have an annual sale of USD 1.0 million and above) have hindered the growth of the market. Increasing mergers and acquisitions of drug manufacturing companies and rapid product launches are some of the major trends in the global hematological diagnostic and therapeutic market.

To view TOC of this report is available upon request @ http://www.persistencemarketresearch.com/toc/4096

The major companies operating in this market are Abbott Laboratories, Amgen, Baxter Healthcare Corporation, Bayer Healthcare Pharmaceuticals, Biogen Idec, Inc., Bristol-Myers Squibb, C.R. Bard, Inc, Eli Lilly and Company, GE Healthcare, GlaxoSmithKline, Pfizer, Sanofi, Siemens AG, and Teva Pharmaceutical Industries Ltd.

About Us

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Contact Us

Persistence Market Research

305 Broadway

7th Floor, New York City, 

NY 10007, United States,

USA - Canada Toll Free: 800-961-0353

Email: sales@persistencemarketresearch.com

Web: http://www.persistencemarketresearch.com

Comments (0)

Add comment

Comment